{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:01:08Z","timestamp":1740106868360,"version":"3.37.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T00:00:00Z","timestamp":1563408000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T00:00:00Z","timestamp":1563408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s00262-019-02370-4","type":"journal-article","created":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T04:55:47Z","timestamp":1563425747000},"page":"1331-1340","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immunity to X-linked inhibitor of apoptosis protein (XIAP) in malignant melanoma and check-point blockade"],"prefix":"10.1007","volume":"68","author":[{"given":"Jun","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Indira","family":"Guleria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Giobbie-Hurder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meghna","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinqi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan C.","family":"Brennick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"Manos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6825-091X","authenticated-orcid":false,"given":"F. Stephen","family":"Hodi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,18]]},"reference":[{"issue":"20","key":"2370_CR1","doi-asserted-by":"publisher","first-page":"7183","DOI":"10.1158\/0008-5472.CAN-04-1918","volume":"64","author":"AD Schimmer","year":"2004","unstructured":"Schimmer AD (2004) Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 64(20):7183\u20137190","journal-title":"Cancer Res"},{"issue":"1","key":"2370_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1535-6108(03)00332-5","volume":"5","author":"AD Schimmer","year":"2004","unstructured":"Schimmer AD et al (2004) Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 5(1):25\u201335","journal-title":"Cancer Cell"},{"issue":"4","key":"2370_CR3","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1158\/1078-0432.CCR-03-0817","volume":"11","author":"S Idenoue","year":"2005","unstructured":"Idenoue S et al (2005) A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins. Clin Cancer Res 11(4):1474\u20131482","journal-title":"Clin Cancer Res"},{"issue":"20","key":"2370_CR4","doi-asserted-by":"publisher","first-page":"5995","DOI":"10.1158\/1078-0432.CCR-07-0729","volume":"13","author":"D Vucic","year":"2007","unstructured":"Vucic D, Fairbrother WJ (2007) The inhibitor of apoptosis proteins as therapeutic targets in cancer. Clin Cancer Res 13(20):5995\u20136000","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2370_CR5","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nrc3237","volume":"12","author":"M Vanneman","year":"2012","unstructured":"Vanneman M, Dranoff G (2012) Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 12(4):237\u2013251","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"2370_CR6","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.humimm.2007.03.007","volume":"68","author":"M Piesche","year":"2007","unstructured":"Piesche M et al (2007) Identification of a promiscuous HLA DR-restricted T-cell epitope derived from the inhibitor of apoptosis protein survivin. Hum Immunol 68(7):572\u2013576","journal-title":"Hum Immunol"},{"issue":"3","key":"2370_CR7","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1158\/1078-0432.CCR-06-1722","volume":"13","author":"M Grube","year":"2007","unstructured":"Grube M et al (2007) CD8\u2009+\u2009T cells reactive to survivin antigen in patients with multiple myeloma. Clin Cancer Res 13(3):1053\u20131060","journal-title":"Clin Cancer Res"},{"issue":"15","key":"2370_CR8","first-page":"4507","volume":"63","author":"C Casati","year":"2003","unstructured":"Casati C et al (2003) The apoptosis inhibitor protein survivin induces tumor-specific CD8\u2009+\u2009and CD4\u2009+\u2009T cells in colorectal cancer patients. Cancer Res 63(15):4507\u20134515","journal-title":"Cancer Res"},{"issue":"5","key":"2370_CR9","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s00262-011-1124-1","volume":"61","author":"J Zhou","year":"2012","unstructured":"Zhou J et al (2012) Immunity to the melanoma inhibitor of apoptosis protein (ML-IAP; livin) in patients with malignant melanoma. Cancer Immunol Immunother 61(5):655\u2013665","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"2370_CR10","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1046\/j.0022-202X.2004.22242.x","volume":"122","author":"MH Andersen","year":"2004","unstructured":"Andersen MH et al (2004) The melanoma inhibitor of apoptosis protein: a target for spontaneous cytotoxic T cell responses. J Invest Dermatol 122(2):392\u2013399","journal-title":"J Invest Dermatol"},{"issue":"6","key":"2370_CR11","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1073\/pnas.0530311100","volume":"100","author":"JC Schmollinger","year":"2003","unstructured":"Schmollinger JC et al (2003) Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc Natl Acad Sci U S A 100(6):3398\u20133403","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2370_CR12","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/j.1600-0560.2007.00798.x","volume":"35","author":"PO Emanuel","year":"2008","unstructured":"Emanuel PO et al (2008) Immunohistochemical detection of XIAP in melanoma. J Cutan Pathol 35(3):292\u2013297","journal-title":"J Cutan Pathol"},{"key":"2370_CR13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1479-5876-5-6","volume":"5","author":"HM Kluger","year":"2007","unstructured":"Kluger HM et al (2007) The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization. J Transl Med 5:6","journal-title":"J Transl Med"},{"issue":"2","key":"2370_CR14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.anndiagpath.2007.04.008","volume":"12","author":"DE Burstein","year":"2008","unstructured":"Burstein DE et al (2008) Immunohistochemical detection of the X-linked inhibitor of apoptosis protein (XIAP) in cervical squamous intraepithelial neoplasia and squamous carcinoma. Ann Diagn Pathol 12(2):85\u201389","journal-title":"Ann Diagn Pathol"},{"issue":"1","key":"2370_CR15","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41467-018-02862-4","volume":"9","author":"WC Hsieh","year":"2018","unstructured":"Hsieh WC et al (2018) IL-6 receptor blockade corrects defects of XIAP-deficient regulatory T cells. Nat Commun 9(1):463","journal-title":"Nat Commun"},{"key":"2370_CR16","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s00262-011-1124-1","volume":"61","author":"J Zhou","year":"2012","unstructured":"Zhou J et al (2012) Immunity to the melanoma inhibitor of apoptosis protein (ML-IAP; livin) in patients with malignant melanoma. Cancer Immunol Immunother 61:655\u2013665","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"2370_CR17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1158\/2326-6066.CIR-14-0184","volume":"3","author":"J Zhou","year":"2015","unstructured":"Zhou J et al (2015) Immunity to the vacuolar ATPase complex accessory unit ATP6S1 in patients with malignant melanoma. Cancer Immunol Res 3(1):59\u201367","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"2370_CR18","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.humpath.2004.03.011","volume":"35","author":"U Ramp","year":"2004","unstructured":"Ramp U et al (2004) XIAP expression is an independent prognostic marker in clear-cell renal carcinomas. Hum Pathol 35(8):1022\u20131028","journal-title":"Hum Pathol"},{"key":"2370_CR19","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13014-015-0437-1","volume":"10","author":"L Flanagan","year":"2015","unstructured":"Flanagan L et al (2015) High levels of X-linked Inhibitor-of-Apoptosis Protein (XIAP) are indicative of radio chemotherapy resistance in rectal cancer. Radiat Oncol 10:131","journal-title":"Radiat Oncol"},{"key":"2370_CR20","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1471-2407-14-24","volume":"14","author":"AV Paschall","year":"2014","unstructured":"Paschall AV et al (2014) Ceramide targets xIAP and cIAP1 to sensitize metastatic colon and breast cancer cells to apoptosis induction to suppress tumor progression. BMC Cancer 14:24","journal-title":"BMC Cancer"},{"issue":"8","key":"2370_CR21","first-page":"2468","volume":"7","author":"CG Ferreira","year":"2001","unstructured":"Ferreira CG et al (2001) Expression of X-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small cell lung cancer patients. Clin Cancer Res 7(8):2468\u20132474","journal-title":"Clin Cancer Res"},{"key":"2370_CR22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev.immunol.17.1.51","volume":"17","author":"JW Yewdell","year":"1999","unstructured":"Yewdell JW, Bennink JR (1999) Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol 17:51\u201388","journal-title":"Annu Rev Immunol"},{"issue":"12","key":"2370_CR23","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1158\/1078-0432.CCR-07-4782","volume":"14","author":"T Sittler","year":"2008","unstructured":"Sittler T et al (2008) Concerted potent humoral immune responses to autoantigens are associated with tumor destruction and favorable clinical outcomes without autoimmunity. Clin Cancer Res 14(12):3896\u20133905","journal-title":"Clin Cancer Res"},{"issue":"16","key":"2370_CR24","first-page":"4499","volume":"60","author":"D Valmori","year":"2000","unstructured":"Valmori D et al (2000) Naturally occurring human lymphocyte antigen-A2 restricted CD8\u2009+\u2009T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res 60(16):4499\u20134506","journal-title":"Cancer Res"},{"issue":"6","key":"2370_CR25","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.immuni.2014.12.005","volume":"41","author":"PT Sage","year":"2014","unstructured":"Sage PT et al (2014) The coinhibitory receptor CTLA-4 controls B cell responses by modulating T follicular helper, T follicular regulatory, and T regulatory cells. Immunity 41(6):1026\u20131039","journal-title":"Immunity"},{"issue":"2","key":"2370_CR26","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/ni.2496","volume":"14","author":"PT Sage","year":"2013","unstructured":"Sage PT et al (2013) The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood. Nat Immunol 14(2):152\u2013161","journal-title":"Nat Immunol"},{"issue":"5617","key":"2370_CR27","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1126\/science.1082305","volume":"300","author":"DJ Shedlock","year":"2003","unstructured":"Shedlock DJ, Shen H (2003) Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300(5617):337\u2013339","journal-title":"Science"},{"issue":"5","key":"2370_CR28","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1084\/jem.189.5.753","volume":"189","author":"RE Toes","year":"1999","unstructured":"Toes RE et al (1999) CD4 T cells and their role in antitumor immune responses. J Exp Med 189(5):753\u2013756","journal-title":"J Exp Med"},{"issue":"12","key":"2370_CR29","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1084\/jem.188.12.2357","volume":"188","author":"K Hung","year":"1998","unstructured":"Hung K et al (1998) The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 188(12):2357\u20132368","journal-title":"J Exp Med"},{"issue":"5","key":"2370_CR30","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1084\/jem.187.5.693","volume":"187","author":"F Ossendorp","year":"1998","unstructured":"Ossendorp F et al (1998) Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 187(5):693\u2013702","journal-title":"J Exp Med"},{"issue":"3","key":"2370_CR31","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1084\/jem.20091918","volume":"207","author":"SA Quezada","year":"2010","unstructured":"Quezada SA et al (2010) Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 207(3):637\u2013650","journal-title":"J Exp Med"},{"issue":"25","key":"2370_CR32","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1056\/NEJMoa0800251","volume":"358","author":"NN Hunder","year":"2008","unstructured":"Hunder NN et al (2008) Treatment of metastatic melanoma with autologous CD4\u2009+\u2009T cells against NY-ESO-1. N Engl J Med 358(25):2698\u20132703","journal-title":"N Engl J Med"},{"issue":"10","key":"2370_CR33","doi-asserted-by":"publisher","first-page":"6919","DOI":"10.1073\/pnas.102025999","volume":"99","author":"FS Hodi","year":"2002","unstructured":"Hodi FS et al (2002) ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction. Proc Natl Acad Sci U S A 99(10):6919\u20136924","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2370_CR34","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1158\/2326-6066.CIR-13-0068","volume":"1","author":"S Kitano","year":"2013","unstructured":"Kitano S et al (2013) Enhancement of tumor-reactive cytotoxic CD4\u2009+\u2009T cell responses after ipilimumab treatment in four advanced melanoma patients. Cancer Immunol Res 1(4):235\u2013244","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"2370_CR35","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1479-5876-2-12","volume":"2","author":"R Srinivasan","year":"2004","unstructured":"Srinivasan R, Wolchok JD (2004) Tumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccines. J Transl Med 2(1):12","journal-title":"J Transl Med"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-019-02370-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-019-02370-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-019-02370-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T23:10:50Z","timestamp":1594941050000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-019-02370-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,18]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["2370"],"URL":"https:\/\/doi.org\/10.1007\/s00262-019-02370-4","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"type":"print","value":"0340-7004"},{"type":"electronic","value":"1432-0851"}],"subject":[],"published":{"date-parts":[[2019,7,18]]},"assertion":[{"value":"30 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Hodi reports grant funding from Bristol-Myers Squibb to institution; personal fees from Bristol-Myers Squibb, Merck, EMD Serono, Novartis, Celldex, Amgen, Genentech\/Roche, Incyte, Apricity, Bayer, Aduro, Partners Therapeutics, Sanofi, Pfizer, Pionyr, 7 Hills Pharma, Verastem, Torque, Compass Therapeutics, Takeda; In addition, Dr. Hodi has a patent Methods for Treating MICA-Related Disorders (#20100111973) with royalties paid, a patent Tumor antigens and uses thereof (#7250291) issued, a patent Angiopoiten-2 Biomarkers Predictive of Anti-immune check-point response (#20170248603) pending, a patent Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Melanoma using PD-L1 Isoforms (#20160340407) pending, a patent Therapeutic peptides (#20160046716) pending, a patent Therapeutic Peptides (#20140004112) pending, a patent Therapeutic Peptides (#20170022275) pending, a patent Therapeutic Peptides (#20170008962) pending, a patent Therapeutic Peptides patent number: 9402905 issued, and a patent Methods of using Pembrolizumab and Trebananib pending. The authors declare that there are no other conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All tumor and blood samples were collected in accordance with the Dana-Farber Harvard Cancer Center Institutional Review Board (IRB)-approved protocol (IRB # 05-042). Informed consent was obtained from melanoma patients to collect and analyze blood and tumor samples for the study of immune function. The informed consent outlines specific uses for blood and tumor, which include but are not limited to PBMC processing and analysis, cell line generation. Informed consent was waived for healthy donors since they are anonymous.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"K008, K028, K029, K033, M13, and M23 melanoma cell lines were generated from tumor biopsies of melanoma patients in accordance with Dana-Farber\/Harvard Cancer Center Institutional Review Board approved protocols. A375 cells were obtained from the ATCC. Expression of MITF in all melanoma cell lines were confirmed. Comparisons of short tandem repeat profiling with cell line DNA profiles were conducted to authenticate the cell line after the project was completed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Cell line authentication"}}]}}